Brief: Medicus Pharma Advances Transformation Into A Precision Oncology-Led Biotechnology Company
08/09/2026 12:48
BRIEF-Medicus Pharma Advances Transformation Into A Precision Oncology-Led Biotechnology Company Sept 8 (Reuters) - Medicus Pharma Ltd MDCX.O:
MEDICUS PHARMA ADVANCES TRANSFORMATION INTO A PRECISION ONCOLOGY-LED BIOTECHNOLOGY COMPANY
MEDICUS PHARMA - CD228V ESTABLISHED AS PRINCIPAL STRATEGIC PRIORITY FOR MEDICUS PHARMA
Source text: ID:nGNX51rfjL
Further company coverage: MDCX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medicus Pharma
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT CONTINUES HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Medicus Pharma Submits Optimized Teverelix® Registrational Protocol To FDA To Create Partner Ready Program In Advanced Prostate Cancer